Exenatide
Exendin-4 / Byetta / Bydureon
- Peptide length
- 39 amino acids
Exendin-4 peptide
Open the sources to check how the studies were done and what they can support.
A GLP-1 receptor agonist used in diabetes medicines with immediate-release and extended-release formulations.
- Family
- Exendin-derived incretin agonist
- Research target
- GLP-1 receptor
- Molecular form
- Exendin-4 peptide
What to know about the research
Formulation determines exposure and administration characteristics. Evidence and labeling for one product do not automatically transfer to another.
Check the exact compound
Distinguish the active peptide from its depot formulation and confirm terminal amidation.
What supports this entry?
The reference list is available. A statement-by-statement source check has not been completed for this entry.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
How we prepare and correct these entries